FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.
Participants will be randomized to either mirvetuximab soravtansine or investigator's choice chemotherapy.
Inclusion Criteria:
Exclusion Criteria:
Augusta, Georgia 30912, United States
Albuquerque, New Mexico 87131, United States
New York, New York 10065, United States
Ostrava Poruba, 708 52, Czechia
Meldola (FC), 47014, Italy
Novosibirsk, 630108, Russia
Omsk, 644013, Russia
Saint Petersburg, 191014, Russia
Nottingham, England NG5 1PB, United Kingdom
Preston, England PR2 9HT, United Kingdom
Sutton, England SM2 5PT, United Kingdom
Wolverhampton, England WV10 OQP, United Kingdom
Stoke-on-Trent, Staffordshire ST4 6QG, United Kingdom
Coventry, CV2 2DX, United Kingdom